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Abstract
Background: There are gaps between what family practitioners do in clinical practice and the
evidence-based ideal. The most commonly used strategy to narrow these gaps is the printed
educational message (PEM); however, the attributes of successful printed educational messages and
their overall effectiveness in changing physician practice are not clear. The current endeavor aims
to determine whether such messages change prescribing quality in primary care practice, and
whether these effects differ with the format of the message.
Methods/design: The design is a large, simple, factorial, unblinded cluster-randomized controlled
trial. PEMs will be distributed with informed, a quarterly evidence-based synopsis of current clinical
information produced by the Institute for Clinical Evaluative Sciences, Toronto, Canada, and will
be sent to all eligible general and family practitioners in Ontario. There will be three replicates of
the trial, with three different educational messages, each aimed at narrowing a specific evidence-
practice gap as follows: 1) angiotensin-converting enzyme inhibitors, hypertension treatment, and
cholesterol lowering agents for diabetes; 2) retinal screening for diabetes; and 3) diuretics for
hypertension.
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For each of the three replicates there will be three intervention groups. The first group will receive
informed with an attached postcard-sized, short, directive "outsert." The second intervention
group will receive informed with a two-page explanatory "insert" on the same topic. The third
intervention group will receive informed, with both the above-mentioned outsert and insert. The
control group will receive informed only, without either an outsert or insert.
Routinely collected physician billing, prescription, and hospital data found in Ontario's
administrative databases will be used to monitor pre-defined prescribing changes relevant and
specific to each replicate, following delivery of the educational messages. Multi-level modeling will
be used to study patterns in physician-prescribing quality over four quarters, before and after each
of the three interventions. Subgroup analyses will be performed to assess the association between
the characteristics of the physician's place of practice and target behaviours.
A further analysis of the immediate and delayed impacts of the PEMs will be performed using time-
series analysis and interventional, auto-regressive, integrated moving average modeling.
Trial registration number: Current controlled trial ISRCTN72772651.
Background
There are gaps between the evidence-based, ideal clinical
practice and what family practitioners (FPs) actually do.
We understand very little about the reasons for these gaps
[1]. Printed educational messages (PEMs), ranging from
short directive statements to long guidelines, have often
been used in the hope of narrowing these gaps [2], but
there is profound uncertainty around their usefulness [3-
5]. PEMs fell into disfavour among researchers in this field
after a 1997 systematic review found their effects to be
uncertain [6]. A recent larger overview found a median
absolute improvement of 8% (range 4–17%) [7].
However, no review can overcome the limitations of the
primary evidence: the small number of trials (each one of
which is small in size), and their continued methodolog-
ical weaknesses (insufficient power to detect modest
effects, and unit of analysis errors).
Aims and objectives
1. To conduct a large, reliable and relevant (pragmatic),
randomized controlled trial of the effect of printed educa-
tional messages (PEMs) on guideline adherence among
Ontario primary care physicians.
2. To determine whether there is any difference in impact
on physician guideline adherence between: 1) a postcard-
sized, short, directive message, 2) a two-page, longer,
explanatory message, or 3) a combination of both.
3. To determine the relative effectiveness of PEMs in nar-
rowing gaps for different health problems.
A randomised trial will help define the role of PEMs,
while increasing our understanding of the process of
implementing evidence of effectiveness into daily clinical
care [8,9].(In Canadian research, the word 'translation' is
used, in place of 'implementation'.)
Methods/design
Pragmatic, randomized controlled trials are reliable eval-
uations of the effectiveness of often complex health care
interventions carried out under real-world conditions
[8,9].
Effectiveness of the intervention usually is assessed by
impact on simple outcomes of importance to users of the
intervention, such as: death, disability, user satisfaction,
utilization of care, and quality of life. Pragmatic trials are
attuned to the same criteria of effectiveness as those used
by policymakers – important and visible outcomes in
usual health service planning entities, and under typical
service limitations. Pragmatic trials take into account the
varied ways that interventions are implemented in the real
world. In contrast, classic explanatory randomized trials
(efficacy trials) test the effects of an intervention, often a
drug, under idealised and tightly controlled conditions,
and on narrowly defined groups of individual patients.
Classic efficacy trials usually are carried out to advance
medical knowledge, whereas pragmatic trials are con-
cerned with assessing the effects of interventions as they
are usually used, in typical settings, and on typical users.
Choice of target physician practices
We used several criteria to identify evidence/practice gaps
important in primary care: the gap involves a common
disorder in Canadian primary care; evidence-based prac-
tice is not constrained by structural, financial or other bar-
riers; the evidence/practice gap is large and may cause
patient harm or unnecessary cost; well-tested process indi-
cators exist that are measurable using administrative data-
sets; and the gaps span a range of clinical practice
behaviours.Implementation Science 2007, 2:37 http://www.implementationscience.com/content/2/1/37
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As a result, we selected three evidence-practice gaps lead-
ing to clinical choices that family doctors should make
more often. These gaps are based upon Ontario adminis-
trative data.
1. Prescription of angiotensin-converting enzyme (ACE)
inhibitors, aggressive hypertension treatment, and choles-
terol-lowering treatment for persons with diabetes (each
falls short of guideline targets by at least 30%) [10-33].
2. Referral of persons with diabetes for eye screening by an
optometrist or ophthalmologist (50% below guideline-
recommended levels) [34-40].
3. Prescription of diuretics as first-line therapy for newly
diagnosed hypertension (~40% below guideline-recom-
mended levels) [41-50].
Trail intervention: the printed educational messages
We will develop PEMs to address each of the three identi-
fied evidence/practice gaps, using input from a diverse
group of physicians to identify barriers to evidence-based
practice and from a communications consultant to inform
design of the messages [51].
The PEMs will be distributed along with informed, a peer-
reviewed, evidence-based practice synopsis, which has
been mailed quarterly since 1994 to nearly 15,000 pri-
mary care providers in Ontario. Subscription is voluntary
and is at no cost to the subscriber. Articles for each eight-
page issue are developed by clinical and research staff
from the Institute for Clinical Evaluative Sciences (ICES),
Toronto, Canada.
Two PEMs will be developed for each of the three evi-
dence/practice gaps:
￿ A short, directive, evidence-based PEM on a postcard-
sized card (referred to as an outsert) stapled to the lower-
left quarter of the front page of informed.
￿ A longer two-page insert (indistinguishable from the rest
of the periodical in size, style and editing) focusing on the
same topic as the outsert, but excluding the directive state-
ments and including more background, evidence-based
guidelines and references.
Research design
The research design is a factorial, cluster-randomized con-
trolled trial with three replicates [52,53]. informed is pub-
lished four times per year. We will conduct three replicates
of the trial to cover the three evidence-practice gaps over a
nine-month period (three successive mailouts of
informed). We will test the effects of short (directive) and
long (discursive) PEMs compared with no PEM on the
clinical practices of primary care physicians, and on
related patient outcomes. Table 1 describes the interven-
tion groups for each of the three replicates. In the first rep-
licate (ACE inhibitors, hypertension treatment, and
cholesterol-lowering agents for diabetes), the first inter-
vention group will receive a copy of informed with both
the short, directive, evidence-based outsert stapled to the
lower-left quarter of the front page, and the longer two-
page insert focusing on the same topic as the outsert. The
second intervention group will receive the identical
informed, with only the above-mentioned outsert. The
third intervention group will receive the identical copy of
informed with the above-mentioned insert. The control
group will receive the identical informed only, without the
insert or the outsert. The health care topic shared by the
insert and outsert will not be covered elsewhere in that
issue of informed. The outsert for this first replicate is
shown in Figure 1 and the insert in Figures 2 and 3.
For the second replicate (retinal screening in patients with
diabetes), in addition to the short, directive outsert and
the longer, explanatory insert, we will add a reminder note
that physicians could give to their patients to supplement
the verbal reminder that we encourage physicians to give.
Because it is not clear whether this patient-held reminder
to make an appointment with their eye care provider is
any more effective than the verbal reminder that we will
encourage physicians to give, we will randomize those
physicians receiving an outsert to receive a pad of the
patient-aimed reminder slips.
For the third replicate (using thiazides as first-line treat-
ment for hypertension), we will use two different short-
directive outsert messages (in addition to the long,
explanatory insert message). Our OPEM team will
develop the first outsert message, whereas a team of psy-
chologists with experience in knowledge implementation
and the use of psychological theories will develop the sec-
ond outsert message. With the addition of a theory-based
outsert, we will be able to determine whether a message
that is based on psychological theory, specifically on the
Theory of Planned Behaviour, will be more effective in
changing clinical behaviour toward more evidence-based
practice than a message that is based on 'standard' meth-
ods, which are uninformed by an explicit theoretical
basis[54]. (See "Ancillary Studies" below.)
Allocating participants to trial groups
Trials of interventions aimed at changing clinical practices
must be randomized at the level at which they are directed
– that is, at the level of the doctor, not his or her patients.
In group practices, however, doctors may well share infor-
mation. To prevent contamination, randomization must
take place at the level of the group rather than the individ-
ual practitioner. A group practice is defined here as all pri-Implementation Science 2007, 2:37 http://www.implementationscience.com/content/2/1/37
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Printed educational message "outsert" for replicate 1 Figure 1
Printed educational message "outsert" for replicate 1.
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Printed Educational Message "Insert" for Replicate 1 (part 1) Figure 2
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Printed Educational Message "Insert" for Replicate 1 (part 2) Figure 3
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mary care physicians who share a common street address,
or who share a common office number in a multi-office
building. The eligible Ontario primary care doctors will be
fee-for-service family physicians (FPs) and general practi-
tioners (GPs) (Ontario Health Insurance Program [OHIP]
billing code 00).
These practitioners will be identified from the health care
providers database held at ICES. They will be verified to be
in active practice. In order to enable prescribing outcomes
to be measured, we will ensure that they have an adequate
volume of seniors among their patients by requiring that
they write at least 100 prescriptions appearing in the ODB
(Ontario Drug Benefit Program) database in the year prior
to enrollment. The physician identifier obtained from
these ODB claims first will be linked to the physician's
College of Physicians and Surgeons of Ontario (CPSO)
number at ICES. Addresses of practitioners will be
obtained by hand-linking the CPSO number to the CPSO
database, which is publicly available on the Internet. The
CPSO website can be queried by CPSO number and will
supply physician name and practice address.
All FPs and some GPs are already on the informed mailing
list. Those who are not currently on the list will be added
for the three intervention issues of informed. This list will
be sorted by addresses of practitioners into practices, in
order to prevent practitioners with the same address, who
may share administrative staff or communicate readily
with each other, from being randomized to different
groups (i.e., to reduce contamination). Using a computer-
generated sequence of random numbers, the practices will
then be randomized to one of the intervention groups.
For each of the three replicates, we will re-randomize phy-
sician practices to one of the intervention groups.
The relevant patients for each practice are defined as any
patient attending that practice who meets study entry cri-
teria. For each of the gaps, we are using a different algo-
rithm to identify relevant patients (see Table 2). A patient
may be counted multiple times, as they are free to attend
more than one primary care practice. This approach is
conservative, and gives all physicians "credit" for appro-
priate prescribing or referral decisions made by any of the
physicians who saw that patient during the study period.
In a sensitivity analysis, we will use a more rigorous rule
for defining physician-patient relationships, whereby
patients will be assigned only to the primary care provider
with whom they had a plurality of their visits. In a tie, the
patient will be assigned to the primary care physician who
wrote the greatest number of their prescriptions during
the study period. Patients who still cannot be unambigu-
ously assigned will be allocated randomly to one of the
practitioners who have written prescriptions for them dur-
ing the study period.
The Registered Persons Database (RPDB) identifies all
persons in the province who are eligible for OHIP cover-
age. It will be used to link patient participants to the
administrative databases, and to detect death and out-
migration of patients over the course of the study. Claims
from the ODB Program will be used to measure the pre-
scribing changes that result from the interventions. These
data are available only for people 65 years of age and
older. Accordingly, the two drug-related replicates are
restricted to that age group of the Ontario population. The
Table 1: Description of the intervention groups within each of the three replicates
REPLICATE 1: Assertive hypertension and cholesterol treatment in patients with Diabetes
INSERT No INSERT
OUTSERT 1. Insert & Outsert 2. Outsert only
NO OUTSERT 3. Insert Only 4. No PEM
REPLICATE 2: Retinal Screening for Patients with Diabetes
Insert No insert
OUTSERT Patient Reminder Note 1. Insert & Outsert & Patient Reminder 2. Outsert & Patient Reminder Note
No Patient Reminder Note 3. Insert & Outsert 4. Outsert only
NO OUTSERT 5. Insert Only 6. No PEM
REPLICATE 3: Diuretics for first-line treatment of hypertension
Insert No insert
OUTSERT Theory-based Outsert 1. Insert & Theory-based Outsert 2. Theory-based Outsert Only
Non-theory-based outsert 3. Insert & Non-theory-based Outsert 4. Non-theory-based Outsert only
NO OUTSERT 5. Insert Only 6. No PEMImplementation Science 2007, 2:37 http://www.implementationscience.com/content/2/1/37
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ODB data are delivered to ICES within two weeks of the
end of the month of the claim. Claims data from OHIP
will be used to identify physician patient linkages, and to
measure the delivery of ophthalmologic and optometric
screening. All of these datasets are available at ICES, and
all bear encrypted health card numbers that are unique to
patients but common over time and across data sets.
Outcome measurement
Follow-up by means of routine data will cover four quar-
ters before and after each prescribing-related PEM inter-
vention. Each of the process-of-care measures has been
used in large-scale studies using databases held at ICES.
Proposed sample size
We wished to have adequate power to detect modest
changes in the way physicians practice. Based on the
median absolute effectiveness of PEMs estimated from the
Grimshaw review (8%) [7], it would be important to
detect 5% and 10% absolute improvements in our target
behaviours. Even 5% improvements in the prevalence of
evidence-based care for these common conditions will be
an important achievement, with significant health bene-
fits for many Ontarians.
In pilot data, the baseline-prescribing rate of ACE inhibi-
tors in persons with diabetes was 36%, and the intra-class
correlation for ACE inhibitor use by patients clustered
within physicians was 9.2%. With an assumption that
one-half of doctors work in solo practices, we ran these
data testing power at a mean of three patients and ten
patients per practice. Monte Carlo simulations demon-
strated that a trial with 1250 practices per arm, with 10
patients per practice and an alpha of 0.05 will provide
more than 98% power to detect a 10% absolute increase
in the rate of ACE inhibitor use, more than 97% power to
detect a 5% absolute increase, and more than 98% power
to distinguish between the effects of the combined inter-
vention and either alone, assuming the combined effect to
be additive.
Because the baseline rates of the other interventions are
comparable or lower (screening for retinopathy, diuretic
use, aggressive blood pressure-reducing, and cholesterol-
lowering therapies), and the number of patients per prac-
titioner with these conditions is the same or higher, we
will have adequate power to detect similar absolute
increases for those endpoints.
Later, with the addition (see Table 1) of two groups in the
second (patient reminder note) and third (theory-based
outsert) replicates, a less comprehensive, but approximate
simulation suggested that the impact on power would be
minor and would most certainly be greater than the often
used target of 80%. The research opportunity that this
modification presented was judged to outweigh the likely
loss of power. Therefore, we maintained 1,250 practices in
the two groups that did not receive an outsert with
informed, and assigned 625 practices to each of the four
groups who were sent an outsert.
Recruitment, compliance, loss to follow-up, and drop-out
Practitioners may of course decide to ignore the PEMs or
never open the envelope containing informed. We will not
know what practitioners will do with the intervention, a
normal feature of the pragmatic trial philosophy that tests
interventions under real-world conditions. informed will
be mailed in the usual fashion to all identified practition-
ers. Any practitioners who subsequently remove them-
selves from the mailing list for informed will be analysed
in the allocated arm on an intention-to-treat basis.
While the unit of analysis is the physician, loss of patients
is important to detect in order to maintain accurate
denominators for the determination of outcome rates.
Patients may be lost due to removal from the system
(death or out-migration), or change of provider. The
Table 2: Patient population and primary outcome for each of 3 replicates
Replicate Evidence/Practice Gap Patients studied Expected 
patient N
Primary Outcome
1 Use of ACE inhibitors, blood 
pressure and cholesterol-reducing 
drugs (ABCs); each fall short of 
guideline targets by at least 30%
All prevalent cases of persons 
with diabetes, aged ≥ 65 years
280,000 % of target patients receiving an 
ACE inhibitor, % receiving 2 or 
more antihypertensive, and % 
receiving lipid-lowering drug
2 Retinopathy screening in incident 
Type 2 DM; 50% below guideline-
recommended levels
All incident cases of persons 
with diabetes, aged >30 years
100,000 % of target patients receiving 
complete eye exam from 
optometrist or ophthalmologist
3 Use of hydrochlorothiazide (HCTZ) 
as initial therapy in uncomplicated 
hypertension; ~40% below guideline-
recommended levels
All patients ≥ 65 years, newly 
initiated on antihypertensive 
therapy
30,000 % of target patients receiving a 
diureticImplementation Science 2007, 2:37 http://www.implementationscience.com/content/2/1/37
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former will be detected in the RPDB, the latter by a plural-
ity rule for prescriptions. For the baseline analysis (pre-
intervention period), the initially assigned patients for
each physician will be used. For each of the succeeding
observation periods (three pre- and four post-interven-
tion), initial patients will be confirmed by eliminating
patients no longer eligible according to the RPDB, and
ensuring that assigned patients are still being cared for by
the study physician through a requirement that the study
physician must have written the plurality of the patient's
prescriptions in that period.
Analyses
We hypothesize that the active intervention arms will be
superior to control, similarly effective to each other, and
with some additive effect when both are delivered. Analy-
ses will be concentrated on this hypothesis.
The study employs a cluster randomized design. The anal-
ysis will be carried out using multi-level, hierarchical,
logistic regression models, with the trial arm being a phy-
sician-level variable, and the prescribing (or screening)
outcome a patient-level variable. These models account
for clustering of patients within practices, and the conse-
quent lack of independence of prescribing outcomes
within a given physician's place of practice [55]. No place-
of-practice characteristics, aside from the arm of the trial
and baseline adherence to guidelines, will be entered into
the model in the primary analysis. With so many physi-
cians randomized to each arm, we anticipate that meas-
ured and unmeasured physician factors that might affect
the outcome will be equally distributed between the arms.
Moreover, including more place-of-practice characteristics
in the model would reduce the statistical power to detect
the primary outcome.
Subgroup analyses
Failure to consistently implement evidence into improved
prescribing decisions has been associated with older phy-
sicians and those without specialty certification [56].
While we would like to test the impact of certification, no
data exists describing this status that can be linked to our
datasets.
Evidence-practice gaps also have been associated with
physician reimbursement arrangements, patient volumes,
physician gender, site and extent of training, group size,
and work load [57]. Thus, we plan subgroup analyses of
male versus female physicians, location of practice (urban
or rural), practice volume, solo versus group practice, and
years since graduation. As before, multilevel, logistic
regression models will be used to assess the association
between place-of-practice characteristics and target behav-
iours.
A further analysis of the immediate and delayed impacts
of the printed educational material will be performed
using time-series analysis and interventional, autoregres-
sive, integrated moving average (ARIMA) modeling [58].
The group to which the patient's practitioner was rand-
omized will be included as a covariate. An immediate
change will be defined as a significant shift in prescribing
patterns from projected estimates within four months of
the intervention. Delayed effects will be measured with
simple time-series analysis, such as exponential smooth-
ing and ARIMA models by comparing actual with pre-
dicted utilization estimates. Stationarity will be assessed
using the autocorrelation function and the augmented
Dickey-Fuller test [59]. The auto-correlation, partial auto-
correlation, and inverse autocorrelation functions will be
assessed for model parameter appropriateness and sea-
sonality. The presence of white noise will be assessed by
examining the autocorrelations at various lags using the
Ljung-Box test [60].
The question of whether there are differences in response
to PEMs for different diseases patient health status levels
and health care problems is addressed in the replicates.
Differences between these replicates will be discussed, and
will not a priori be subjected to meta-analysis. In the event
of substantial homogeneity of outcomes, we will consider
meta-analysis across the replicates.
There will be one analysis for each replicate upon receipt
of one year of follow-up data.
Ancillary studies
Two smaller studies will be conducted in conjunction
with the OPEM study. Both will take advantage of the
infrastructure, which will already be in place for the main
study to obtain additional, related information about
PEMs – namely information about the causal mechanisms
through which PEMs lead to behaviour changes.
The Testing a TheoRY-informed Message (TRY-ME) study
will be associated with the third intervention (prescrip-
tion of diuretics as first-line therapy for newly diagnosed
hypertension) [64]. Two outserts will be developed. The
wording of the first outsert containing a 'standard' mes-
sage will be developed by a team of clinical researchers
experienced in implementation research and in the devel-
opment of short educational messages directed to clini-
cians. The wording of the second, theory-based message
will be developed by a team of psychologists with experi-
ence in implementation research, and clinical researchers
experienced in the use of psychological theories. Other-
wise, the two messages will use similar styles, font sizes
and colours. As indicated in the above "Proposed Sample
Size" sub-section, the OPEM study will retain sufficientImplementation Science 2007, 2:37 http://www.implementationscience.com/content/2/1/37
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power for the primary outcomes, while also permitting a
comparison of 'standard' and theory-based outserts.
The interpretation of the results of the OPEM trial and
assessment of its likely generalisability would be
enhanced if we had additional information about the
causal mechanisms through which the interventions
worked, and how these were modified in the presence of
different barriers and enablers. The second ancillary study
will conduct a theory-based process evaluation alongside
the OPEM trail. "Looking inside the black box: a theory-
based process evaluation alongside a randomised control-
led trial of printed educational materials" [65] will
develop surveys, based upon the Theory of Planned Behav-
iour [56], for the second and third OPEM interventions,
and survey a sub-sample of recipients from each arm of
the trial two months before and six months after the dis-
semination of the relevant edition of informed.
Ethical approval
This study has received approval from the Research Ethics
Board at Sunnybrook and Women's College Health Sci-
ences Centre. The data linkage processes described above
have been used at ICES previously, and meet the require-
ments of the ICES research agreement with the Ontario
Ministry of Health and Long-Term Care, under which
ICES has access to the administrative data.
Discussion
We understand very little about the reasons for the gaps
between what family practitioners do in clinical practice,
and what the evidence-based ideal says they should do.
The simplest intervention to narrow these gaps is the
PEM, ranging from a one-sentence directive to a long
guideline; and they have often been used, but in an intui-
tive fashion, with neither an underlying theory of behav-
iour change nor a deep understanding of physicians'
barriers to change.
After a 1997 systematic review found their effects to be
uncertain, PEMs fell into disfavour. However, a more
recent and larger overview found a median improvement
of 8% in comparison with no PEM – a result which was
similar in effect to more expensive and intensive strate-
gies. Nevertheless, this review cannot overcome the limi-
tations of the primary evidence: the small number of trials
(each one of which is small in size), and their continued
methodological weaknesses (insufficient power to detect
modest effects, and unit of analysis errors). More evidence
is needed in order to decide whether PEMs can be used to
help change clinical practice.
We have proposed a trial that is designed to address these
shortcomings. The large size of the trial provides enough
power to confidently and precisely delineate modest
effects. Modest effects are important, given the large abso-
lute impact that is achievable when the intervention is
applied to a common health problem. By randomizing at
the level of the physician place-of-practice, the trial avoids
contamination and unit of analysis error. In addition to
answering the question of whether PEMs change primary
care practitioners' therapeutic decisions, this study, along
with its two ancillary studies, also will compare the
impact of two types of PEMs (the short, directive versus a
two-page descriptive message), and will examine the con-
textual and sociological factors (e.g., health problems,
location, style of physician practice and duration of prac-
tice) which may influence the impact of PEMs.
If passive dissemination of PEMs is shown to be effective,
this study may give professional, administrative, and
patient organizations interested in change toward evi-
dence-based practice the impetus to develop systematic
programs for practice change using PEMs. If shown to be
ineffective, use of PEMs as a single practice change inter-
vention would be discouraged, thereby eliminating waste
and turning research attention toward other interven-
tions, including a possible role for PEMs as one element
in a multi-faceted intervention. If effectiveness is shown to
vary by disease problem, barrier, subgroup of practitioner,
or any other factor, this study will help inform how differ-
ent kinds of PEMs should be used in different situations
and health problems.
While no economic analysis has been proposed, pending
a determination of the effectiveness of PEMs in changing
practice, we will collect all costs attributable solely to PEM
development, design and dissemination. If the interven-
tion is effective, we will work to set up an initial cost anal-
ysis, in which the health care utilization and prescribing
changes, if any, of the intervention will be assessed in view
of the marginal costs of the PEM intervention. We also
will approach professional bodies and patient advocacy
groups to offer help in developing PEM strategies for
health care quality improvement.
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